Find Bismuth Subgallate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 99-26-3, Bismuthsubgallate, Wismutgallathydroxid, Gallic acid bismuth basic salt, Bismuth gallate, Dermatol puder
Molecular Formula
C7H6BiO6
Molecular Weight
395.10  g/mol
InChI Key
XXCBNHDMGIZPQF-UHFFFAOYSA-L

Bismuth Subgallate
Bismuth subgallate is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight. It is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed. Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet elucidated antimicrobial and hemostatic actions, bismuth subgallate is most commonly available as an over-the-counter internal deodorant where it is often employed as the primary active ingredient.
1 2D Structure

Bismuth Subgallate

2 Identification
2.1 Computed Descriptors
2.1.1 InChI
InChI=1S/C7H6O5.Bi.H2O/c8-4-1-3(7(11)12)2-5(9)6(4)10;;/h1-2,8-10H,(H,11,12);;1H2/q;+2;/p-2
2.1.2 InChI Key
XXCBNHDMGIZPQF-UHFFFAOYSA-L
2.1.3 Canonical SMILES
C1=C(C=C2C(=C1O)O[Bi]O2)C(=O)O.O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Bismuth Subgallate Hydrate

2. Dermatol Ointment

2.2.2 Depositor-Supplied Synonyms

1. 99-26-3

2. Bismuthsubgallate

3. Wismutgallathydroxid

4. Gallic Acid Bismuth Basic Salt

5. Bismuth Gallate

6. Dermatol Puder

7. 2,7-dihydroxy-1,3,2-benzodioxabismole-5-carboxylic Acid

8. Basic Bismuth 3,4,5-trihydroxybenzoate

9. Ncgc00166280-01

10. Bismuth Subgallas

11. Bismutum Subgallicum

12. Wismutgallat, Basisches

13. Caswell No. 098b

14. 2,7-dihydroxybenzo[d][1,3,2]dioxabismole-5-carboxylic Acid

15. Dermatol

16. Bismuth(iii) Gallate Basic Hydrate

17. Einecs 202-742-2

18. Unii-yiw503mi7v

19. Epa Pesticide Chemical Code 098601

20. Bismuth-subgallate

21. Dermatol (tn)

22. Bismuth Subgallate [usan:usp:jan]

23. Basisches Wismutgallat

24. 1,3,2-benzodioxabismole-5-carboxylic Acid, 2,7-dihydroxy-

25. Bismuth 3,4,5-trihydroxybenzoate, Basic

26. Dihydroxy(3,4,5-trihydroxybenzoato-o')bismuth

27. Schembl7892

28. Dsstox_cid_26588

29. Dsstox_rid_81746

30. Dsstox_gsid_46588

31. Bismuth, Dihydroxy(3,4,5-trihydroxybenzoato-o')-

32. Dtxsid3046588

33. Bismuth Subgallate (jp17/usp)

34. Chebi:31292

35. Bismuth(iii) Gallate, Basic

36. Hy-b1560

37. Tox21_112388

38. Mfcd00044980

39. Db13909

40. Cas-99-26-3

41. Ncgc00166280-02

42. Cs-0013442

43. D01398

44. E75771

2.3 Create Date
2007-08-23
3 Chemical and Physical Properties
Molecular Weight 395.10 g/mol
Molecular Formula C7H6BiO6
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count1
Exact Mass394.99684 g/mol
Monoisotopic Mass394.99684 g/mol
Topological Polar Surface Area77 Ų
Heavy Atom Count14
Formal Charge0
Complexity222
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

The most common medical purpose for which bismuth subgallate is currently and formally indicated for is the use as a non-prescription internal deodorant product for the purpose of deodorizing flatulence and stools. Additionally, there are also various non-prescription (over the counter) bismuth subgallate based wound healing products as well as ongoing studies into whether or not the substance can be utilized as a legitimate hemostatic agent - usually for soft tissue surgery in otorhinolaryngology and/or dermatologic settings. Moreover, in the past bismuth subgallate may have seen some use as a treatment for Helicobacter pylori infection. In contrast, contemporary first-line therapies generally involve proton pump inhibitor and antibiotic combination therapies that generally achieve high rates of pathogen eradication, ease of administration, and patient compliance.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Bismuth subgallate is a heavy metal salt that is relatively insoluble and poorly absorbed. As a result, systemic absorption is not necessary or possibly even desired when the agent is administered orally or onto specific otorhinolaryngology and/or dermatologic wound sites where it can execute its pharmacologic action directly within the gastrointestinal lumen to deodorize flatulence and stools or potentially elicit a hemostatic effect on wounds. Additionally, like other bismuth agents, one of the most common side effects associated with bismuth subgallate is its propensity to cause a black discoloration of the tongue and stools when the agent combines with trace amounts of sulfur in the saliva and/or gastrointestinal tract. This discoloration is temporary and harmless, gradually dissipating over a number of days and eventually disappearing after the discontinuation of the bismuth agent.


5.2 MeSH Pharmacological Classification

Anti-Infective Agents

Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)


Hemostatics

Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)


5.3 FDA Pharmacological Classification
5.3.1 Pharmacological Classes
Bismuth [EPC]; Bismuth [CS]
5.4 Absorption, Distribution and Excretion

Absorption

Bismuth subgallate is only slightly, if at all, absorbed after oral ingestion. The general human oral bioavailability of bismuth subgallate has been reported as low as 0.04%. Any absorption that does occur is likely to happen from the upper small intestine. The gastrointestinal absorption of bismuth from bismuth compounds demonstrates a large interindividual variation. Factors affecting the absorption involve the formulation of the bismuth subgallate compound as well as the dietary factors of the individuals themselves. Nevertheless, absorption can be enhanced with the concomitant intake of citrate and sulfhydryl-group-containing compounds. Conversely, the simultaneous administration of antacids or a diet that is high in thiol content can lower absorption of bismuth subgallate.


Route of Elimination

Ingested bismuth is primarily eliminated unabsorbed by way of the faeces. Any absorbed bismuth is eliminated from the body by both the urinary and faecal (including bile) routes. Excretion of absorbed bismuth in the urine is rapid, with most of the metal excreted within 24 hours. About 10% of the absorbed bismuth is detected in faeces, presumably owing to biliary secretion.


Volume of Distribution

In general, oral administration is one of the most common routes of administration for non-prescription bismuth subgallate products and gastrointestinal and systemic absorption is usually very low.


Clearance

On average, the blood clearance of the bismuth component of a bismuth salt like bismuth subgallate is within the range of 50 to 95 ml/min.


5.5 Metabolism/Metabolites

No specific metabolism of bismuth is known. In the kidney it induces the de novo synthesis of a bismuth-metal-binding protein, which is a kind of methallothionein.


5.6 Biological Half-Life

The bismuth component of bismuth subgallate is known to have a terminal half-life of 21-72 days.


5.7 Mechanism of Action

Bismuth salts exert their action largely in the upper gastrointestinal tract by way of local activity from luminal bismuth in the stomach and duodenum. In terms of bismuth subgallate's ability to deodorize flatulence and stools as an internal deodorant - although not fully elucidated - it is believed that when the substance is administered orally, its relative insolubility and poor absorption allows it to remain within the gastrointestinal lumen and inhibit colonic bacteria from acting on fermentable food residues in the GI tract. Moreover, when bismuth subgallate is taken orally, various salts like bismuth citrate, bismuth oxychloride, and others are formed. These salts are then taken up into surrounding gastric mucus as well as bound to protein within the base of any ulcers that may be present after coming into contact with gastric juice. Additionally, bismuth compounds like bismuth subgallate are also believed to have the capacity to trigger the secretion of prostaglandins, epithelial growth factor (EGF), and mucosal bicarbonate as a means to inhibit the action of pepsin in gastric juice. These actions subsequently protect gastric mucous from peptic luminal degradation as well as enhance the properties of mucous to assist in the healing of both duodenal and gastric ulcers. In this way, bismuth subgallate works to absorb extra water and/or toxins in the large intestine, allowing it to form a protective coat on the intestinal mucosa and over ulcers that may or may not be associated with infections like those of Helicobacter pylori. Furthermore, studies have shown that bismuth compounds like bismuth subgallate are capable of demonstrating antimicrobial effects against various gastrointestinal tract pathogens like E. coli, Salmonella, Shigella, Vibrio cholera, Campylobacter jejuni, H. pylori, and some enteric viruses like Rotaviruses. Although the exact mechanism(s) of action by which bismuth compounds are able to elicit such antimicrobial effects remains unclear, a number of experimental observations suggest that bismuth has been able to complex with the bacterial wall and periplasmic membrane; inhibit bacterial enzymes like urease, catalase, and lipase; inhibit bacterial protein and ATP synthesis; and also inhibit or decrease the adherence of bacteria like H. pylori to epithelial cells. In essence, ultrastructural studies have shown evidence of the binding of bismuth complexes to the bacterial wall and periplasmic space between the inner and outer bacterial membrane of H.pylori with subsequent ballooning and disintegration of the pathogen. To various extents, these antimicrobial actions may also illustrate how bismuth subgallate is capable of neutralizing colonic bacteria from acting on fermentable foods as well. Numerous studies have and continue to study the possible hemostatic action that bismuth subgallate may have. As the bismuth salt of gallic acid, bismuth subgallate's chemical structure shares similarities to ellagic acid, another gallic acid derivative. Ellagic acid itself is a clot-promoting agent that initiates thrombin formation by way of the intrinsic pathway via an action on Hageman factor (clotting factor XII). It is believed that bismuth subgallate's ability to activate factor XII is associated with the chemical's negatively charged moieties - whose contact with factor XII would theoretically initiate the intrinsic pathway to blood clotting. Other studies have also suggested that bismuth subgallate is capable of inducing macrophages to secrete growth factors to facilitate wound healing, decreasing lesion area, enhancing granulation tissue formation and re-epithelialization, the initiation of the proliferation of collagen via the activation of fibroblasts, the accelerated re-establishment of blood vessels, and also the restriction of nitric oxide formation. Given such studies regarding bismuth subgallate's potential hemostatic abilities, there has been and continues to be interest in indicating the agent for use in otolaryngology as in tonsillectomies or adenotonsillectomies to achieve reduced bleeding and surgery times; topical treatment in various open wound surgeries to facilitate faster and earlier clotting between tissues; ileostomy; dental surgeries; epistaxis management; among others. Nevertheless, study results are conflicting; where there may be experimental results suggesting some improvements in reduced operation time and operative blood loss when bismuth subgallate is used as a hemostatic agent in tonsillectomies there are also study results that observed bismuth subgallate having a negative influence on the healing processes of wounds inflicted in animal models, in which the use of the agent actually delayed the rate of new vessel formation and optimal wound healing. Finally, bismuth subgallate also demonstrates a strong astringent ability - an action that can facilitate both its deodorant and hemostatic effects and assists in its indication as an active ingredient in a number of non-prescription products for hemorrhoid suppositories or topical applications, diarrhea, etc.


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"BISMUTH SUBGALLATE","year":"2021","qtr":"Q1","strtotime":1616092200,"product":"BISMUTH SUBGALLATE HYDRATE (500 GM)","address":"GOPAL NIVAS139 S G MARG (PRINCESS ST)","city":"BOMBAY ,MAHARASHTRA","supplier":"J PAREKH & ","supplierCountry":"INDIA","foreign_port":"MOMBASA","customer":"NEBRIX LIMITED","customerCountry":"KENYA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"1049.6","totalValueFC":"563.2","currency":"USD","unitRateINR":82000,"date":"19-Mar-2021","totalValueINR":"41000","totalValueInUsd":"563.2","indian_port":"JNPT","hs_no":"29182990","bill_no":"9477614","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"KENYA","selfForZScoreResived":"Pharma Grade","supplierPort":"JNPT","supplierAddress":"GOPAL NIVAS139 S G MARG (PRINCESS ST), BOMBAY ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648146600,"product":"BULK DRUG:- BISMUTH SUBGALLATE USP 43 (M","address":"A-201\/202, NAVBHARAT EST.,,ZAKARIA BUNDER RD.,SEWRI WEST,","city":"MUMBAI,MAHARASHTRA","supplier":"GEMINI EXPORTS","supplierCountry":"INDIA","foreign_port":"LAPAZ","customer":"THE","customerCountry":"BOLIVIA","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"89","totalValueFC":"1587.5","currency":"USD","unitRateINR":4840,"date":"25-Mar-2022","totalValueINR":"121000","totalValueInUsd":"1587.5","indian_port":"BOMBAY AIR","hs_no":"29182190","bill_no":"9201780","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BOLIVIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-201\/202, NAVBHARAT EST.,,ZAKARIA BUNDER RD.,SEWRI WEST,, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662057000,"product":"BULK DRUG- BISMUTH SUBGALLATE USP 2022 (","address":"A-201\/202, NAVBHARAT EST.,,ZAKARIA BUNDER RD.,SEWRI WEST,","city":"MUMBAI,MAHARASHTRA","supplier":"GEMINI EXPORTS","supplierCountry":"INDIA","foreign_port":"LAPAZ","customer":"THE","customerCountry":"BOLIVIA","quantity":"75.00","actualQuantity":"75","unit":"KGS","unitRateFc":"90","totalValueFC":"5440.4","currency":"USD","unitRateINR":5813.333333333333,"date":"02-Sep-2022","totalValueINR":"436000","totalValueInUsd":"5440.4","indian_port":"BOMBAY AIR","hs_no":"29182190","bill_no":"3916055","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BOLIVIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-201\/202, NAVBHARAT EST.,,ZAKARIA BUNDER RD.,SEWRI WEST,, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1701455400,"product":"PHARMA. RAW MATERIAL-BULK DRUG\/EXCIPIENTS\/FOR PHARMACEUTICAL INDUS.BISMUTH SUBGALLATE USP","address":"708, TIMES SQUARE ARCADE,","city":"AHMEDABAD","supplier":"SKJ HEALTHCARE PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"UMM QASR","customer":"TO THE ORDER OF","customerCountry":"IRAQ","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"42.5","totalValueFC":"1597.7","currency":"USD","unitRateINR":3325,"date":"02-Dec-2023","totalValueINR":"133000","totalValueInUsd":"1597.7","indian_port":"Ahmedabad ICD","hs_no":"29182190","bill_no":"5760449","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAQ","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad ICD","supplierAddress":"708, TIMES SQUARE ARCADE,, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705429800,"product":"PHARMA. RAW MATERIAL-BULK DRUG\/EXCIPIENTS\/FOR PHARMACEUTICAL INDUS:BISMUTH SUBGALLATE USP","address":"708, TIMES SQUARE ARCADE,","city":"AHMEDABAD","supplier":"SKJ HEALTHCARE PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"UMM QASR","customer":"TO THE ORDER OF UMM QASR IRAQ","customerCountry":"IRAQ","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"42.5","totalValueFC":"1192.7","currency":"USD","unitRateINR":3304.3633333333332,"date":"17-Jan-2024","totalValueINR":"99130.9","totalValueInUsd":"1192.7","indian_port":"Ahmedabad ICD","hs_no":"29182190","bill_no":"6818973","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAQ","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad ICD","supplierAddress":"708, TIMES SQUARE ARCADE,, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722796200,"product":"RAW MATERIAL - BISMUTH SUBGALLATE","address":"306 A-WING HARI OM PLAZA M G ROAD","city":"MUMBAI M S","supplier":"AURA PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"KINSHASA","customer":"TO,","customerCountry":"CONGO D REPULIC","quantity":"300.00","actualQuantity":"300","unit":"KGS","unitRateFc":"41.5","totalValueFC":"12294.4","currency":"USD","unitRateINR":3437.4467,"date":"05-Aug-2024","totalValueINR":"1031234.01","totalValueInUsd":"12294.4","indian_port":"Bombay Air","hs_no":"29182990","bill_no":"2983071","productDescription":"API","marketType":"REGULATED MARKET","country":"CONGO D REPULIC","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"306 A-WING HARI OM PLAZA M G ROAD, MUMBAI M S","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724351400,"product":"PHARMA. RAW MATERIAL-BULK DRUG\/EXCIPIENTS\/FOR PHARMACEUTICAL INDU:ZONQS-108 (BISMUTH SUBGALLATE USP)","address":"708, TIMES SQUARE ARCADE,","city":"AHMEDABAD","supplier":"SKJ HEALTHCARE PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"UMM QASR","customer":"TO THE ORDER OF\\\" POD: UMM QASR","customerCountry":"IRAQ","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"45","totalValueFC":"395.7","currency":"USD","unitRateINR":3319.0870000000004,"date":"23-Aug-2024","totalValueINR":"33190.87","totalValueInUsd":"395.7","indian_port":"Ahmedabad ICD","hs_no":"29182190","bill_no":"3444692","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAQ","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad ICD","supplierAddress":"708, TIMES SQUARE ARCADE,, AHMEDABAD","customerAddress":""}]
19-Mar-2021
23-Aug-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

USP

read-more
read-more

ABOUT THIS PAGE

Bismuth Subgallate Manufacturers

A Bismuth Subgallate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bismuth Subgallate, including repackagers and relabelers. The FDA regulates Bismuth Subgallate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bismuth Subgallate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Bismuth Subgallate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Bismuth Subgallate Suppliers

A Bismuth Subgallate supplier is an individual or a company that provides Bismuth Subgallate active pharmaceutical ingredient (API) or Bismuth Subgallate finished formulations upon request. The Bismuth Subgallate suppliers may include Bismuth Subgallate API manufacturers, exporters, distributors and traders.

click here to find a list of Bismuth Subgallate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Bismuth Subgallate USDMF

A Bismuth Subgallate DMF (Drug Master File) is a document detailing the whole manufacturing process of Bismuth Subgallate active pharmaceutical ingredient (API) in detail. Different forms of Bismuth Subgallate DMFs exist exist since differing nations have different regulations, such as Bismuth Subgallate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Bismuth Subgallate DMF submitted to regulatory agencies in the US is known as a USDMF. Bismuth Subgallate USDMF includes data on Bismuth Subgallate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bismuth Subgallate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Bismuth Subgallate suppliers with USDMF on PharmaCompass.

Bismuth Subgallate JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Bismuth Subgallate Drug Master File in Japan (Bismuth Subgallate JDMF) empowers Bismuth Subgallate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Bismuth Subgallate JDMF during the approval evaluation for pharmaceutical products. At the time of Bismuth Subgallate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Bismuth Subgallate suppliers with JDMF on PharmaCompass.

Bismuth Subgallate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bismuth Subgallate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Bismuth Subgallate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Bismuth Subgallate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Bismuth Subgallate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bismuth Subgallate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Bismuth Subgallate suppliers with NDC on PharmaCompass.

Bismuth Subgallate GMP

Bismuth Subgallate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Bismuth Subgallate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bismuth Subgallate GMP manufacturer or Bismuth Subgallate GMP API supplier for your needs.

Bismuth Subgallate CoA

A Bismuth Subgallate CoA (Certificate of Analysis) is a formal document that attests to Bismuth Subgallate's compliance with Bismuth Subgallate specifications and serves as a tool for batch-level quality control.

Bismuth Subgallate CoA mostly includes findings from lab analyses of a specific batch. For each Bismuth Subgallate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Bismuth Subgallate may be tested according to a variety of international standards, such as European Pharmacopoeia (Bismuth Subgallate EP), Bismuth Subgallate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bismuth Subgallate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty